Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of Pertuzumab With or Without Other Anti-Cancer Therapies in Patients From Prior Roche Pertuzumab Trials
2023-505102-42-00Phase 3Authorised
- Sponsor
- Roche
- Start
- Dec 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 12
01
Overview
Phase 3, open-label, single-arm trial of pertuzumab in Non-hematologic malignancy, sponsored by Roche. Primary endpoint: Safety and tolerability of pertuzumab. Planned start Dec 2014; status: authorised.
02
Drugs
pertuzumab
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on 2023-505102-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505102-42-00.